{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:59:05Z","timestamp":1793498345836,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bcp.2021.114700","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T07:12:25Z","timestamp":1627024345000},"page":"114700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Oncogenic activity and cellular functionality of melanoma associated antigen A3"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1082-923X","authenticated-orcid":false,"given":"Paula","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Paraschiakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114700_b0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases","volume":"262","author":"Coley","year":"1991","journal-title":"1893, Clin. Orthop. Relat. Res."},{"issue":"9","key":"10.1016\/j.bcp.2021.114700_b0010","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2021.114700_b0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114700_b0020","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.2910390320","article-title":"Production of stable cytolytic T-cell clones directed against autologous human melanoma","volume":"39","author":"H\u00e9rin","year":"1987","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2021.114700_b0025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.179.3.921","article-title":"Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes","volume":"179","author":"Gaugler","year":"1994","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.bcp.2021.114700_b0030","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jmb.2017.03.005","article-title":"A comprehensive guide to the MAGE family of ubiquitin ligases","volume":"429","author":"Lee","year":"2017","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2021.114700_b0035","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1128\/MCB.19.11.7327","article-title":"DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter","volume":"19","author":"De Smet","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"24","key":"10.1016\/j.bcp.2021.114700_b0040","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine","volume":"64","author":"Sigalotti","year":"2004","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2021.114700_b0045","first-page":"4773","article-title":"Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles","volume":"61","author":"Kobayashi","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2021.114700_b0050","unstructured":"M.D. Bethesda, National Center for Biotechnology Information, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda MD, 20894 USA, 1988."},{"issue":"2","key":"10.1016\/j.bcp.2021.114700_b0055","doi-asserted-by":"crossref","first-page":"e0148762","DOI":"10.1371\/journal.pone.0148762","article-title":"Structures of two melanoma-associated antigens suggest allosteric regulation of effector binding","volume":"11","author":"Newman","year":"2016","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.bcp.2021.114700_b0060","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/sj.jid.5700836","article-title":"Epigenetic control of MAGE gene expression by the KIT tyrosine kinase","volume":"127","author":"Yang","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114700_b0065","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-07-2003","article-title":"Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia","volume":"14","author":"Zhu","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.bcp.2021.114700_b0070","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1158\/0008-5472.CAN-08-2132","article-title":"The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114700_b0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.bbrc.2020.09.115","article-title":"LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma progression by regulating MAGEA3 and DCAF4L2 expression","volume":"533","author":"Zhang","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2021.114700_b0080","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13046-019-1272-2","article-title":"Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells","volume":"38","author":"Das","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114700_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109710","article-title":"Aberrantly enhanced melanoma-associated antigen (MAGE)-A3 expression facilitates cervical cancer cell proliferation and metastasis via actuating Wnt signaling pathway","volume":"122","author":"Gao","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bcp.2021.114700_b0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.18632\/oncotarget.27488","article-title":"MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21(Cip1)","volume":"11","author":"Mei","year":"2020","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2021.114700_b0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13402-015-0261-5","article-title":"Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer","volume":"39","author":"Xie","year":"2016","journal-title":"Cell Oncol (Dordr)"},{"issue":"3","key":"10.1016\/j.bcp.2021.114700_b0100","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3892\/ol.2017.5665","article-title":"Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer","volume":"13","author":"Chen","year":"2017","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.bcp.2021.114700_b0105","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/(SICI)1097-0215(19961021)69:5<403::AID-IJC9>3.0.CO;2-9","article-title":"Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma","volume":"69","author":"Corrias","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2021.114700_b0110","doi-asserted-by":"crossref","DOI":"10.1196\/annals.1322.008","article-title":"Immunogenicity of human neuroblastoma","volume":"1028","author":"Prigione","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2021.114700_b0115","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00432-008-0484-1","article-title":"MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors","volume":"135","author":"Grau","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3b","key":"10.1016\/j.bcp.2021.114700_b0120","first-page":"2205","article-title":"Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma","volume":"19","author":"S\u00f6ling","year":"1999","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2021.114700_b0125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19961021)69:5<375::AID-IJC4>3.0.CO;2-2","article-title":"MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors","volume":"69","author":"Ishida","year":"1996","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2021.114700_b0130","author":"Pollard","year":"2008","journal-title":"Cell Biol."},{"issue":"20","key":"10.1016\/j.bcp.2021.114700_b0135","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1158\/0008-5472.CAN-07-1478","article-title":"MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2021.114700_b0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.molcel.2010.08.029","article-title":"MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases","volume":"39","author":"Doyle","year":"2010","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.bcp.2021.114700_b0145","doi-asserted-by":"crossref","first-page":"e23747","DOI":"10.1371\/journal.pone.0023747","article-title":"MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression","volume":"6","author":"Xiao","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114700_b0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.abb.2014.07.026","article-title":"MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity","volume":"563","author":"Xiao","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"8","key":"10.1016\/j.bcp.2021.114700_b0155","doi-asserted-by":"crossref","first-page":"995","DOI":"10.7150\/ijms.42805","article-title":"Inhibitor of differentiation 1 (Id1) in cancer and cancer therapy","volume":"17","author":"Zhao","year":"2020","journal-title":"Int. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2021.114700_b0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell. Physiol."},{"issue":"34","key":"10.1016\/j.bcp.2021.114700_b0165","doi-asserted-by":"crossref","first-page":"23780","DOI":"10.18632\/oncotarget.25267","article-title":"p53 and metabolism: from mechanism to therapeutics","volume":"9","author":"Simabuco","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2021.114700_b0170","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cdd.2017.174","article-title":"Mechanisms of transcriptional regulation by p53","volume":"25","author":"Sullivan","year":"2018","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.bcp.2021.114700_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081178","article-title":"p21 in cancer research","volume":"11","author":"Shamloo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2021.114700_b0180","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cell.2015.01.034","article-title":"Degradation of AMPK by a cancer-specific ubiquitin ligase","volume":"160","author":"Pineda","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bcp.2021.114700_b0185","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/15548627.2015.1034420","article-title":"Oncogenic MAGEA-TRIM28 ubiquitin ligase downregulates autophagy by ubiquitinating and degrading AMPK in cancer","volume":"11","author":"Pineda","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2021.114700_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.07.031","article-title":"miR-1273g silences MAGEA3\/6 to inhibit human colorectal cancer cell growth via activation of AMPK signaling","volume":"435","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2021.114700_b0195","doi-asserted-by":"crossref","unstructured":"X. Jin, Y. Pan, L. Wang, L. Zhang, R. Ravichandran, P.R. Potts, J. Jiang, H. Wu, H. Huang, MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBP1 for degradation, Oncogenesis 6(4) (2017) e312.","DOI":"10.1038\/oncsis.2017.21"},{"issue":"11","key":"10.1016\/j.bcp.2021.114700_b0200","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/94.11.805","article-title":"Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?","volume":"94","author":"Parmiani","year":"2002","journal-title":"J. Natl Cancer Inst."},{"issue":"1","key":"10.1016\/j.bcp.2021.114700_b0205","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0959-8049(02)00479-3","article-title":"Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report","volume":"39","author":"Marchand","year":"2003","journal-title":"Eur. J. Cancer"},{"issue":"19","key":"10.1016\/j.bcp.2021.114700_b0210","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114700_b0215","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114700_b0220","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2021.114700_b0225","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.27939","article-title":"Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes","volume":"132","author":"Russo","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2021.114700_b0230","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.vaccine.2013.12.049","article-title":"Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector","volume":"32","author":"Batchu","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.bcp.2021.114700_b0235","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1078-0432.CCR-13-2817","article-title":"Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3\/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells","volume":"20","author":"Rapoport","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114700_b0240","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1186\/s12885-018-5193-9","article-title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma","volume":"18","author":"McQuade","year":"2018","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2021.114700_b0245","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and challenges of adoptive T-cell therapies for solid tumours","volume":"124","author":"Morotti","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2021.114700_b0250","doi-asserted-by":"crossref","unstructured":"B.J. Cameron, A.B. Gerry, J. Dukes, J.V. Harper, V. Kannan, F.C. Bianchi, F. Grand, J.E. Brewer, M. Gupta, G. Plesa, G. Bossi, A. Vuidepot, A.S. Powlesland, A. Legg, K.J. Adams, A.D. Bennett, N.J. Pumphrey, D.D. Williams, G. Binder-Scholl, I. Kulikovskaya, B.L. Levine, J.L. Riley, A. Varela-Rohena, E.A. Stadtmauer, A.P. Rapoport, G.P. Linette, C.H. June, N.J. Hassan, M. Kalos, B.K. Jakobsen, Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells, Sci Transl Med 5(197) (2013) 197ra103.","DOI":"10.1126\/scitranslmed.3006034"},{"issue":"6","key":"10.1016\/j.bcp.2021.114700_b0255","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2021.114700_b0260","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"issue":"29","key":"10.1016\/j.bcp.2021.114700_b0265","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","article-title":"Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3","volume":"35","author":"Lu","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114700_b0270","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.bcp.2021.114700_b0275","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00262-011-1037-z","article-title":"MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing","volume":"60","author":"Bao","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"Suppl","key":"10.1016\/j.bcp.2021.114700_b0280","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"14","key":"10.1016\/j.bcp.2021.114700_b0285","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.7150\/ijms.27643","article-title":"Cancer\/testis antigen MAGEA3 interacts with STAT1 and remodels the tumor microenvironment","volume":"15","author":"Wang","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.bcp.2021.114700_b0290","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3389\/fgene.2020.01002","article-title":"Identification of an immune-related prognostic signature associated with immune infiltration in melanoma","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Genet."},{"issue":"2","key":"10.1016\/j.bcp.2021.114700_b0295","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.abb.2011.01.007","article-title":"Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1","volume":"508","author":"Bhatia","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.bcp.2021.114700_b0300","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bjc.2012.215","article-title":"Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma","volume":"107","author":"Dyrskj\u00f8t","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2021.114700_b0305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CJI.0000000000000013","article-title":"Expression of MAGE-A3\/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival","volume":"37","author":"Ayyoub","year":"2014","journal-title":"J. Immunother."},{"issue":"4","key":"10.1016\/j.bcp.2021.114700_b0310","first-page":"3513","article-title":"Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma","volume":"8","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Exp Pathol"},{"issue":"5","key":"10.1016\/j.bcp.2021.114700_b0315","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2009.014464","article-title":"Cancer-testis antigens MAGE-C1\/CT7 and MAGE-A3 promote the survival of multiple myeloma cells","volume":"95","author":"Atanackovic","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bcp.2021.114700_b0320","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2310\/JIM.0b013e31822a2360","article-title":"Melanoma antigen encoding gene-A3 expression, its clinical significance, and its risk of developing acute myeloid leukemia","volume":"59","author":"Makhlouf","year":"2011","journal-title":"J. Invest. Med."},{"issue":"22","key":"10.1016\/j.bcp.2021.114700_b0325","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer","volume":"11","author":"Gure","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2021.114700_b0330","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.18632\/oncotarget.14830","article-title":"MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy","volume":"8","author":"Laban","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bcp.2021.114700_b0335","doi-asserted-by":"crossref","first-page":"e0241551","DOI":"10.1371\/journal.pone.0241551","article-title":"MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.bcp.2021.114700_b0340","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10006-019-00778-x","article-title":"The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis","volume":"23","author":"Trippel","year":"2019","journal-title":"Oral Maxillofac. Surg."},{"issue":"6","key":"10.1016\/j.bcp.2021.114700_b0345","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apm.13132","article-title":"Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer","volume":"129","author":"khalvandi","year":"2021","journal-title":"APMIS"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221003130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:27:05Z","timestamp":1757770025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221003130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":69,"alternative-id":["S0006295221003130"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114700","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncogenic activity and cellular functionality of melanoma associated antigen A3","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114700"}}